Stock CYTRX CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Analyst Reco. CytRx Corporation Nasdaq

Equities

US2328286081

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Patients
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LADX Stock
  4. Stock
  5. News CytRx Corporation
  6. Analyst Reco.